You are here

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Chandler, Arizona, 85226 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bipolar Disorder, Bipolar Depression
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria for Bipolar I disorder, most recent episode depressed, with or
without rapid cycling and without psychotic features. Subjects receive therapeutic
dose of lithium, valproate or lamotrigine for at least 4 weeks prior to randomization.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with ultra-fast rapid cycling (8 or more mood episodes per year)

- Significant heart disease including abnormalities in the heart's rhythm (QT
prolongation)

- Psychotic symptoms (hallucinations and/or delusions).

NCT00483548
Pfizer
Completed
Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now